2022 San Antonio Breast Cancer Symposium SABCS 2022: monarchE Trial of Abemaciclib Plus ET for HR-Positive, HER2-Negative, Node-Positive, High-Risk Early Breast Cancer
2022 San Antonio Breast Cancer Symposium SABCS 2022: First-Line Ribociclib Plus Endocrine Therapy in Patients With Aggressive Breast Cancer
Genitourinary Cancers Radiopharmaceuticals for Treatment of Metastatic Castration-Resistant Prostate Cancer
